Autres langues ARS Pharmaceuticals, Inc.

Actions

SPRY

US82835W1080

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 18/09/2026			Varia. 5j.	Varia. 1 janv.
4,110 ^USD	-0,96%		-13,66%	-64,72%

13/08	ARS Pharmaceuticals : creusement de la perte nette au deuxième trimestre malgré la hausse du chiffre d'affaires	MT
13/08	Transcript : ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026

Autres langues

15/09	LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares - Purchased Between March and June 2026 - Should Contact the Shareholders Foundation
01/09	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
13/08	ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises
13/08	ARS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
13/08	ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
03/08	ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
17/07	Ars Pharmaceuticals, Inc. Announces Management Changes, Effective July 15, 2026
07/07	ARS Pharmaceuticals Announces CEO Succession
07/07	ARS Pharmaceuticals, Inc. Announces Appointment of Donn Casale as Director, Effective July 7, 2026
07/07	ARS Pharmaceuticals, Inc. Announces CEO Changes
01/07	SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud
29/06	ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Defensive Index
29/06	ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Growth-Defensive Index
25/06	MÄRKTE USA/Apple-Preiserhöhungen dämpfen Micron-Euphorie
25/06	MÄRKTE USA/Apple-Preiserhöhungen dämpfen Micron-Euphorie
25/06	MÄRKTE USA/Uneinheitlich - Preiserhöhungen belasten Apple
25/06	MÄRKTE USA/Uneinheitlich - Micron-Zahlen und Inflationsdaten lindern Nervosität
25/06	MÄRKTE USA/Micron-Zahlen dürften für gute Börsenstimmung sorgen
25/06	Top Premarket Decliners
25/06	ARS Pharmaceuticals Updates Neffy Coverage Outlook, Cuts 2026 Costs
24/06	ARS Pharmaceuticals Provides Commercial and Financial Updates
04/06	Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
15/05	ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
15/05	ARS Pharmaceuticals Q1 Loss Widens, Revenue Rises; Shares Up Pre-Bell
15/05	Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss